Clinical/Scientific Note
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
Paul J. Reading PhD, MRCP,
Anna K Luce BSc,
Ian G. McKeith MD, FRCPsych,
Corresponding Author
Paul J. Reading PhD, MRCP
Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UKSearch for more papers by this authorAnna K Luce BSc
Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
Search for more papers by this authorIan G. McKeith MD, FRCPsych
Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
Search for more papers by this authorPaul J. Reading PhD, MRCP,
Anna K Luce BSc,
Ian G. McKeith MD, FRCPsych,
Corresponding Author
Paul J. Reading PhD, MRCP
Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UKSearch for more papers by this authorAnna K Luce BSc
Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
Search for more papers by this authorIan G. McKeith MD, FRCPsych
Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
Search for more papers by this authorAbstract
This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug. © 2001 Movement Disorder Society.
References
- 1Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996; 53: 1265–1268.
- 2Haeske-Dewick HC. Hallucinations in Parkinson's disease: characteristics and associated clinical features. Int J Geriatr Psychiatry 1995; 10: 487–495.
- 3Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease. Arch Neurol 1999; 56: 595–601.
- 4Naimark D, Jackson E, Rockwell, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 1996; 44: 296–299.
- 5Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733–745.
- 6Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139: 494–497.
- 7Moscovitz C, Moses H III, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669–675.
- 8Pappert EJ, Goetz CG, Niederman FG, Rema Raman MS, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999; 14: 117–121.
- 9Pieri V, Diederich NJ, Comella CL. REM sleep disorder in PD patients with and without coexistent hallucinations [Abstract]. Mov Disord 1998; :13(Suppl 2): 274.
- 10Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans KL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5: 183–194.
- 11Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, Agid Y. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000: 55; 281–288.
- 12 Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–763.
- 13Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085–1087.
- 14Juncos JL, Arvanitis L, Sweitzer D, Yeung P, Jewart RD, Nemeroff C. Quetiapine improves psychotic symptoms associated with Parkinson's disease [Abstract]. Neurology 1999; 52(Suppl 2): A262
- 15Friedman FH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201–211.
- 16Graham JM, Sussman JD, Ford KS, Sagar HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998; 65: 774–777.
- 17Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of psychopharmacology. Baltimore: Williams & Wilkins; 1997.
- 18Cummings JL. Managing psychosis in patients with Parkinson's disease. N Engl J Med 1999; 340: 801–803.
- 19Dubois B, Danzé F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 1986; 22: 26–30.
- 20Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47: 876–883.
- 21Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1999; 10: 229–238.
10.1017/S1041610298005341 Google Scholar
- 22Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9(Suppl 2): 8–14.
- 23Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 324–326.
- 24McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000; 15: 387–392.
10.1002/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9 CASPubMedWeb of Science®Google Scholar
- 25McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–2036.
- 26Daniel SE, Lees AJ. Parkinson's disease brain bank, London: overview and research. J Neural Transm 1993; 39(Suppl): 165–172.
- 27Folstein MF, Folstein SE, McHugh PR. “Mini-mental state‘: a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
- 28Fahn S, Elton RL, members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. In: S Fahn, CD Marsden, M Goldstein, DB Calne, editors. Recent developments in Parkinson's disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153–163, 293–304.
- 29Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–2314.
- 30Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 1998; 55: 1313–1319.
- 31Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65: 717–721.
- 32Kollar EJ, Pasnau RO, Rubin RT, Naitoh P, Slater GG, Kales A. Psychological, psychophysiological, and biochemical correlates of prolonged sleep deprivation. Am J Psychiatry 1969; 126: 488–497.
- 33Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 540–543.
- 34Wyatt RJ, Chase TN, Scott J, Snyder F, Engelman K. Effect of L-DOPA on the sleep of man. Nature 1970; 228: 999–1001.
- 35Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34: 710–714.
- 36Steriade M. Basic mechanisms of sleep generation. Neurology 1992; 42(Suppl 6): 9–18.
- 37Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, McKeith IG. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999; 14: 459–466.
10.1002/(SICI)1099-1166(199906)14:6<459::AID-GPS957>3.0.CO;2-R CASPubMedWeb of Science®Google Scholar
- 38Wilcock GK, Scott MI. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 1994; 344: 544.
- 39Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, Lantos P. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994; 343: 176.
